Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Marta, Hájková"'
Autor:
Dragana M. Jovanovic, Martina Šterclová, Nesrin Mogulkoc, Katarzyna Lewandowska, Veronika Müller, Marta Hájková, Michael Studnicka, Jasna Tekavec-Trkanjec, Simona Littnerová, Martina Vašáková, the EMPIRE registry investigators
Publikováno v:
Respiratory Research, Vol 23, Iss 1, Pp 1-13 (2022)
Abstract Background Patients with idiopathic pulmonary fibrosis (IPF) frequently have multiple comorbidities, which may influence survival but go under-recognised in clinical practice. We therefore report comorbidity, antifibrotic treatment use and s
Externí odkaz:
https://doaj.org/article/3e8acd4648c840be8bf8eb43046c6c69
Autor:
Ondřej Májek, Jakub Gregor, Nesrin Mogulkoć, Katarzyna Lewandowska, Martina Šterclová, Veronika Müller, Marta Hájková, Mordechai R Kramer, Jasna Tekavec-Trkanjec, Dragana Jovanović, Michael Studnicka, Natalia Stoeva, Klaus-Uwe Kirchgässler, Simona Littnerová, Ladislav Dušek, Martina Koziar Vašáková
Publikováno v:
PLoS ONE, Vol 17, Iss 9, p e0273854 (2022)
BackgroundThere is no clear evidence whether pirfenidone has a benefit in patients with probable or possible UIP, i.e. when idiopathic pulmonary fibrosis (IPF) is diagnosed with a lower degree of diagnostic certainty. We report on outcomes of treatme
Externí odkaz:
https://doaj.org/article/62d03fd7fced4bb68c72565e31432e8a
Autor:
Abigél Margit Kolonics-Farkas, Martina Šterclová, Nesrin Mogulkoc, Katarzyna Lewandowska, Veronika Müller, Marta Hájková, Mordechai Kramer, Dragana Jovanovic, Jasna Tekavec-Trkanjec, Michael Studnicka, Natalia Stoeva, Simona Littnerová, Martina Vašáková
Publikováno v:
Frontiers in Medicine, Vol 8 (2021)
Idiopathic pulmonary fibrosis (IPF) is a rare lung disease with poor prognosis. The diagnosis and treatment possibilities are dependent on the health systems of countries. Hence, comparison among countries is difficult due to data heterogeneity. Our
Externí odkaz:
https://doaj.org/article/b399851ef6f24b1fa825cc97e6b8ce39
Autor:
Tanja Tran, Martina Šterclová, Nesrin Mogulkoc, Katarzyna Lewandowska, Veronika Müller, Marta Hájková, Mordechai R. Kramer, Dragana Jovanović, Jasna Tekavec-Trkanjec, Michael Studnicka, Natalia Stoeva, Karel Hejduk, Ladislav Dušek, Samy Suissa, Martina Vašáková, for the EMPIRE registry
Publikováno v:
Respiratory Research, Vol 21, Iss 1, Pp 1-9 (2020)
Abstract Background Several registries of idiopathic pulmonary fibrosis (IPF) have been established to better understand its natural history, though their size and duration of follow-up are limited. Here, we describe the large European MultiPartner I
Externí odkaz:
https://doaj.org/article/9d4a56a4f4404f718e7719bee03526fd
Autor:
Dragana M, Jovanovic, Martina, Šterclová, Nesrin, Mogulkoc, Katarzyna, Lewandowska, Veronika, Müller, Marta, Hájková, Michael, Studnicka, Jasna, Tekavec-Trkanjec, Simona, Littnerová, Martina, Vašáková
Background Patients with idiopathic pulmonary fibrosis (IPF) frequently have multiple comorbidities, which may influence survival but go under-recognised in clinical practice. We therefore report comorbidity, antifibrotic treatment use and survival o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::64ed4bd8dcbd0663abf771dbbcf07d71
https://hdl.handle.net/11454/77816
https://hdl.handle.net/11454/77816
Autor:
Imrich Jonner, V. Lostakova, Małgorzata Sobiecka, F. Petrik, Peter Paluch, Martina Plačková, A. Jakic, J. Lnenicka, Štefan Tóth, Hana Suldova, T. Tran, Ladislav Dušek, Martina Sterclova, A. Szymanowska-Narioch, Aleksander Kania, M.J. Studnicka, Jan Anton, T. Stachura, Renata Králová, Pavlina Musilova, Richard Tyl, Mordechai R. Kramer, Marta Hájková, Ladislav Lacina, Martina Doubková, T. Pejcic, Marina Roksandic Milenkovic, L. Borucki, J. Plutinsky, V. Vucinic-Mihailovic, Margita Bučeková, Robert Slivka, Imre Lajkó, Pawel Sliwinski, Sebastian Majewski, A. Nowicka, Bohumil Matula, S. Mladinov, Zoltán Balikó, Ilona Binková, Anikó Bohács, Veronika Müller, P. Jurek, Natalia Stoeva, V. Rihak, Lenka Šišková, Radka Bittenglova, Pavlína Lisá, T. Snizek, Vladimir Bartos, R. Mokosova, Mária Szilasi, S. Suissa, T. R. Petkovic, Zsuzsanna Szalai, D. Jovanovic, Štefan Laššán, D. Dolezal, H. Hortvikova, Nesrin Mogulkoc, Miklós Zsiray, M. Zurkova, Beata Zolnowska, Martina Vasakova, Jana Psikalova, P. Reiterer, Katarzyna Lewandowska, Marzena Trzaska-Sobczak, Jasna Tekavec-Trkanjec, M. Martusewia-Boros, Karel Hejduk, R. Hrdina, Jiří Homolka, R. Vysehradsky
Publikováno v:
Respiratory Research, Vol 21, Iss 1, Pp 1-9 (2020)
Respiratory Research
Respiratory Research
Background Several registries of idiopathic pulmonary fibrosis (IPF) have been established to better understand its natural history, though their size and duration of follow-up are limited. Here, we describe the large European MultiPartner IPF Regist
Autor:
Jasna Tekavec-Trkanjec, Simona Littnerová, Dragana Jovanovic, Ondrej Majek, Marta Hájková, Natalia Stoeva, Klaus Uwe Kirchgässler, Michael Studnicka, Veronika Müller, Jakub Gregor, Nesrin Mogulkoc, Katerzyna Lewandowska, Martina Sterclova, Martina Vasakova
Publikováno v:
Idiopathic interstitial pneumonias.
[No Abstract Available]
Autor:
Veronika Müller, Jasna Tekavec-Trkanjec, Biserka Kaeva, Mordechai R. Kramer, Martina Vasakova, Natalia Stoeva, Michael Studnicka, Martina Sterclova, Nesrin Mogulkoc, Marina Roksandic Milenkovic, Katarzyna Lewandowska, Dragana Jovanovic, Marta Hájková, Simona Littnerová
Publikováno v:
Idiopathic interstitial pneumonias.
Background: A correlation of adverse events (AE), and the efficacy of EGFR TKIs in lung cancer patients (pts) is known. Similar AE are seen in IPF pts treated with triple TKI nintedanib (N) and pirfenidone (P). Post hoc analysis to assess the correla
Autor:
Jasna Tekavec-Trkanjec, Simona Littnerová, Nesrin Mogulkoc, Veronika Müller, Marta Hájková, Dragana Jovanovic, Jan Kus, Abigel Kolonics-Farkas, Karel Hejduk, Martina Sterclova, Martina Vasakova
Publikováno v:
Drug Safety
Introduction Nintedanib, a tyrosine kinase receptor inhibitor, may be associated with increased bleeding risk. Thus, patients with an inherited predisposition to bleeding, or those receiving therapeutic doses of anticoagulants or high-dose antiplatel
Autor:
Natalia Stoeva, M.J. Studnicka, Martina Vasakova, Veronika Müller, Nesrin Mogulkoc, D. Jovanovic, Ladislav Dušek, Simona Littnerová, Martina Sterclova, Katarzyna Lewandowska, Jasna Tekavec-Trkanjec, Marta Hájková
Publikováno v:
A37. ILD THERAPY I.